KEIFEI Retatrutifei Pen 32.5MG (Retatrutide)
Each pre-filled disposable pen for subcutaneous injection contains 32.5mg/ pen of retatruide with pre-mixed powder and solvent solution. No cartridge changes are required — once the pen is empty, simply start a new pen. The pen is non-refillable, sealed in a printed PVC bag featuring the Keifei® logo, and packaged in a printed box with a QR authentication code.
Retatrutide is a synthetic peptide designed as a triple agonist that simultaneously targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). By engaging these key metabolic pathways, Retatrutide has demonstrated significant potential in promoting weight loss, improving glycemic control, and enhancing energy metabolism.
Key Benefits
Significant weight loss through appetite suppression and increased energy expenditure via glucagon receptor activation.
Improved glucose tolerance by enhancing insulin secretion and sensitivity through GIP and GLP-1 receptor pathways.
Reduction in body fat mass while preserving lean muscle, contributing to better body composition.
Cardiometabolic benefits including potential improvements in lipid profiles and blood pressure.
Promising therapeutic potential for obesity and related metabolic disorders, currently under clinical investigation.
Important Note
Retatrutide has demonstrated significant potential for obesity and metabolic disorder management in clinical trials. However, as an investigational drug under clinical evaluation, its use should only be in regulated clinical trials or under strict medical supervision upon approval. Individual responses may vary and potential side effects exist. Always consult a healthcare provider to ensure safe and appropriate use for your specific health condition.